Concise Review:A Safety Assessment of Adipose-Derived Cell Therapy in Clinical Trials:A Systematic Review of Reported Adverse Events by Toyserkani, Navid Mohamadpour et al.
Syddansk Universitet
Concise Review
Toyserkani, Navid; Jørgensen, Mads Gustaf; Tabatabaeifar, Siavosh; Jensen, Charlotte
Harken; Sheikh, Søren Paludan; Sørensen, Jens Ahm
Published in:
Stem Cells Translational Medicine
DOI:
10.1002/sctm.17-0031
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC-ND
Citation for pulished version (APA):
Toyserkani, N. M., Jørgensen, M. G., Tabatabaeifar, S., Jensen, C. H., Sheikh, S. P., & Sørensen, J. A. (2017).
Concise Review: A Safety Assessment of Adipose-Derived Cell Therapy in Clinical Trials:A Systematic Review
of Reported Adverse Events. Stem Cells Translational Medicine, 6(9), 1786–1794. DOI: 10.1002/sctm.17-0031
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 15. okt.. 2017
Concise Review: A Safety Assessment of Adipose-
Derived Cell Therapy in Clinical Trials: A Systematic
Review of Reported Adverse Events
NAVID MOHAMADPOUR TOYSERKANI ,a,b,c MADS GUSTAF JØRGENSEN,a,b,c SIAVOSH TABATABAEIFAR,a,c
CHARLOTTE HARKEN JENSEN,b,d SØREN PALUDAN SHEIKH,b,d,e JENS AHM SØRENSENa,b,c
Key Words. Adipose-derived stromal cells • Stromal vascular fraction • Safety • Adverse events •
Complications
Authored by a member of
ABSTRACT
The popularity of adipose-derived cell therapy has increased over the last decade, and the number
of studies published annually is growing. However, concerns regarding safety in the setting of pre-
vious malignancy or the use of allogeneic cells have been raised. We therefore aimed to systemati-
cally review all clinical studies using adipose-derived cell therapy to identify reported adverse
events with a special focus on risk of thromboembolic, immunological, and oncological safety con-
cerns. Our systematic search resulted in 70 included studies involving more than 1,400 patients
that were treated with adipose-derived cell therapy. Safety assessment method was not described
in 32 of the included studies. For studies involving systemic or cardiac administration, one case of
pulmonary thromboembolism and cases of both myocardial and cerebral infarctions were
described. In the setting of allogeneic cell therapy studies, where the production of speciﬁc anti-
bodies toward donor cells was examined, it was noted that 19%–34% of patients develop antibod-
ies, but the consequence of this is unknown. With regard to oncological safety, only one case of
breast cancer recurrence was identiﬁed out of 121 patients. Adipose-derived cell therapy has so
far shown a favorable safety proﬁle, but safety assessment description has, in general, been of
poor quality, and only adverse events that are looked for will be found. We encourage future stud-
ies to maintain a strong focus on the safety proﬁle of cell therapy, so its safeness can be conﬁrmed.
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SIGNIFICANCE STATEMENT
This study reviewed the safety of adipose-derived cell therapy. Thromboembolic complications
were noted following systemic administration of cells. The treatment has so far shown to be
safe in the setting of previous cancer. Donor-specific antibodies are produced when using allo-
geneic cells, documenting that these cells are not immune privileged. The consequences of this
needs further research. Future research should focus on higher quality of reporting of adverse
events, as the present literature is of low quality.
INTRODUCTION
The ﬁeld of regenerative medicine has been rap-
idly expanding over the last decade and especially
cells derived from adipose tissue have received a
lot of attention due to the ease of harvest and
obtainable number of cells [1, 2]. The cells from
adipose tissue can be used for therapeutic pur-
poses, either freshly isolated as the stromal vascu-
lar fraction (SVF, also called adipose-derived
regenerative cells [ADRC]), or culture-expanded as
the adipose-derived stem cells (ASC). Adipose-
derived cell therapy has shown potential in almost
every preclinical animal model [3–7] and the time
is ripe for clinical translation of this potential.
The ﬁrst results published from a clinical trial
using adipose-derived cell therapy, published in
2005, were for the treatment of Crohn’s ﬁstula
[8]. Since then, a steady increase of publications
and in treated conditions has occurred. However,
as of yet there is still no clear evidence for the
implementation of adipose-derived cell therapy in
the daily clinical routine.
The mechanisms of action of adipose-derived
cell therapy have been hypothesized to be
through different pathways, such as paracrine
secretion of growth factors, cytokines and micro-
RNA promoting angiogenesis and modulating the
immune response, as well as the ability of cells to
differentiate into a variety of different cell types.
However, very rarely can a beneﬁcial effect be
expected without the risk of adverse events. Con-
sequently, safety concerns have been raised
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STANDARDS, PROTOCOLS, POLICIES, AND REGULATIONS
FOR CELL-BASED THERAPIES
regarding the use of systemically administered cell therapy due to
risk of thromboembolic complications [9, 10], the use of allogeneic
cells and possible rejection [11], and in the setting of previous can-
cer therapy [12–14].
The aim of this systematic review was therefore to collect and
review all reported adverse events related to adipose-derived cell
therapy with a focus on thromboembolic, immunological, and
oncological safety concerns.
MATERIALS AND METHODS
This systematic review was reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) statement [15]. A systematic search was performed on
PubMed using the following search string: “([adipose stem cell]
OR [adipose stromal cell] or [adipose regenerative cell] or [stromal
vascular fraction] or [processed lipoaspirate]) AND (trial or trials
or pilot or ‘feasibility study’ or ‘safety study’).” A similar search
was performed on EMBASE. All search results were imported to
Covidence for further evaluation [16]. Study selection was per-
formed by two independent assessors (NMT and & MGJ). First, all
studies were screened based on title and abstract. Secondly, full
text versions of included studies were read for further evaluation.
A hand search was also performed by skimming the references of
included studies.
Inclusion criteria were human studies using adipose-derived
cells for treatment of any given disease published no later than
31st of December 2016. Exclusion criteria were non-English lan-
guage, reviews, case reports, or case series with fewer than ﬁve
patients and animal or in vitro studies.
Data retrieved from included studies were year of publication,
country of origin, disease treated, study design (randomized
controlled trial, nonrandomized study, or case series/pilot study),
primary aim (safety or efﬁcacy), cell type used (freshly isolated or
culture-expanded as well as autologous or allogeneic), cell dosage,
cell characterization (cell count/viability, surface marker analysis,
and ﬁbroblastoid colony forming units assay [CFU-F]), number of
participants, safety reporting described clearly in the Methods
section (yes/no), and the reported adverse events including all-
cause mortality. The primary aim was set to safety if this was
explicitly stated or was mentioned with equal weight as efﬁcacy.
The safety reporting was set to “yes” if anything pertaining to the
evaluation of adverse events was noted in the Methods section,
and it was set to “no” if nothing at all was described.
All studies with a comparison group were also evaluated for
risk of bias using the Cochrane Collaboration tool where safety
was set as outcome measure [17]. In brief, seven aspects are eval-
uated for risk of bias and given an evaluation of either low risk,
unclear, or high risk of bias. The seven aspects are random
sequence generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment, incomplete
outcome data, selective reporting, and other areas of bias.
RESULTS
Description of Included Studies
In total, 907 unique studies were identiﬁed using our search
string. In addition, 10 studies were found through hand search.
After screening title and abstract, 97 studies remained. Full text
evaluation excluded a further 27 studies leaving 70 studies to be
included in the review with a total of 1,474 patients treated with
adipose-derived cell therapy (Fig. 1). Almost all organ system have
been implicated in adipose-derived cell therapy. The indication for
treatment in the included studies was (in order count) soft tissue
Figure 1. Flow chart of article selection process.
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[18–35], gastrointestinal [8, 36–48], musculoskeletal [49–58],
rheumatological [59–63], ulcer/ischemic limb [64–67], urogenital
[68–72], cardiac [73–76], neurological [77–80], immunological
[81–83], pulmonary [84, 85], and ophthalmological [86] (Fig. 2A).
Studies were performed worldwide but Europe and Asia have so
far published the majority of studies using adipose-derived cell
therapy (Fig. 2B).
The majority of studies [43] were small in scale and conducted
as a series of cases without a comparison group. There were eight
studies comparing adipose-derived cell therapy with a nonrandom
control group, and 19 studies were conducted as randomized con-
trolled trials (Fig. 2C). The ﬁrst clinical study using adipose-derived
cell therapy was published in 2005. Since then, a steady rise in
publications has followed with an explosive growth annually since
2012 (Fig. 2D).
Overview
In the included studies ADRC treatment was given in 36 studies,
whereas ASC was used in the 32 studies (two studies included
both ADRC and ASC). The most frequent method to characterize
cells was cell count with viability estimation. Cell dosage was not
speciﬁed in fourteen studies in which the indication was soft
tissue reconstruction [20, 22, 23, 25, 26, 28, 29, 31, 32], gastroin-
testinal [47], musculoskeletal [49], neurological [80], or urogenital
disease [71, 72]. In addition, 38 studies performed surface marker
analysis of cells or at least had set release criteria for certain sur-
face markers in studies using ASCs. CFU-F was performed in only
ten studies.
Almost any cell administration pathway was represented in
the included studies. Remarkably, a total of 32 of 70 studies did
not clearly describe any form of adverse event evaluation in the
Methods section, including four studies in which safety was desig-
nated as the primary outcome [8, 50, 52, 73] (Supporting Informa-
tion Table S1). The severity of adverse events depended on the
underlying condition being treated, but no studies identiﬁed any
adverse event as being related to the adipose-derived cell
therapy.
Thromboembolic Safety and Mortality
For studies administering cells systemically or intramyocardially,
possible thromboembolic complications and all-cause mortality
were evaluated. Three RCT studies and one case series adminis-
tered cells for cardiac indications with various methods.
Figure 2. An overview of included studies. (A): Graphical overview of the range of indications adipose-derived cell therapy has been used
for. (B): Graphical overview of research activity bias on geographic location showing that the majority of included studies are from either
Europe or Asia. (C): The majority of studies were of case series quality with no control group for comparison. Eight of studies included a non-
random control group and 19 studies were randomized studies. (D): Since the ﬁrst publication in 2005 there has been a steady rise in
research output of clinical studies using adipose-derived cell therapy.
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Two double-blinded RCT trials that were published together
administered autologous ADRC intramyocardially with the differ-
ence between the two studies being cell dosage (40 or 80 3 106
cells vs. placebo) [76]. Enrollment was terminated prematurely
due to adverse events. In total, 31 patients were included and 17
received ADRC. Two patients treated with ADRC experienced car-
diac death on day 2 and 291 after administration, and one experi-
enced myocardial infarction at an unknown time point. In
addition, a cerebrovascular event occurred in two patients in the
ADRC group and one in the placebo group within 24 hours of
injection. All neurological symptoms had complete or near-
complete recovery. The RCT study by Houtgraaf et al. administered
ADRC intracoronarily for myocardial infarction with no mention of
speciﬁc thromboembolic complications or deaths [74].
In an RCT study by Perin et al., who administered ADRC trans-
endocardially, one out of 21 patients developed myocardial infarc-
tion immediately following injection and died [75]. One patient
out of six died in the control group. In a case series by Comella
et al., which used a similar administration method for ADRC in 28
patients with chronic ischemic cardiomyopathy, three patients
died after 1, 7, and 12 months [73].
Three RCT studies and two case series administered cells intra-
venously for various indications. One dose-escalating RCT study by
Alvaro-Gracia et al., administered allogeneic ASC intravenously for
the treatment of rheumatoid arthritis and observed a case of lacu-
nar infarction in the low-dose treatment group, eight days after cell
administration [61]. No further thromboembolic events occurred.
Vanikar et al. conducted a three-armed randomized trial
administering ASC together with hematopoietic stem cells versus
hematopoietic stem cells alone versus no cell treatment to mini-
mize rejection following renal transplantation [82]. Herein the dis-
tribution of cardiovascular deaths was not signiﬁcantly different
across the groups of which 6/95 treated with ASCs died of either
cardiovascular or cerebrovascular events compared with 9/190 in
the two other groups combined. The all-cause mortality in
patients treated with ASCs was 7/95 compared with 20/190,
which was not statistically signiﬁcant. The remaining RCT and case
series administering cells systemically or using near-systemic
administration did not describe cases of thromboembolic events
[81, 83, 84]. See Table 1 for overview of reported complications.
The evaluation of thromboembolic complications and mortal-
ity included two subgroups of studies that used either autologous
ADRC for cardiac indications, administered within the heart, or
allogeneic ASC, administered intravenously for a variety of indica-
tions. It can be difﬁcult to assess the mortality rate in studies with-
out a control group, especially considering that the patient
categories included were of poor prognosis to begin with. For the
studies including controls there was no indication of an increased
mortality for patients receiving cell therapy.
Thromboembolic complications were few, and the comparison
across studies was difﬁcult due to heterogeneous cell administra-
tion, as three different administration routes were applied in the
four cardiac studies. It must also be taken into account that the
complications noted were not necessarily due to the cell treat-
ment, as the time frame between cell treatment and complica-
tions was not always clearly described.
Immunological Safety
Possible immunologic complications were noted for studies
administering allogeneic cells (Table 1). This included four RCTs
and seven case series.
Two RCTs evaluated the production of donor-speciﬁc antibod-
ies as a measure of immune reaction. In the study of Panes et al.,
34% of patients without prior IgG HLA class I antibodies generated
anti-HLA class I antibodies during the study period [44]. There
were, however, no noted immune reactions or adverse events
associated with the donor-speciﬁc antibodies, and the presence of
the antibodies was not associated with the therapeutic response.
In another study using similar allogeneic ASC for intravenous
administration, it was noted that 19% of patients developed
donor-speciﬁc antibodies [61]. The most frequent adverse event
was transient fever following cell administration (9/46 treated
patients).
The remaining two RCTs did not evaluate the immune
response to allogeneic cells biochemically. Vanikar et al. conducted
a study in which allogeneic ASC were coinfused with allogeneic
hematopoietic stem cell transplantation; they found no evidence
of graft versus host disease [82]. Zheng et al. described no side
effects during allogeneic ASC infusion in the six treated patients
[84]. Two adverse events were noted the ﬁrst day (1 diarrhea and
1 skin rash) , both of which resolved by the next day.
Two case series evaluated the possibility of immune reaction
by measuring the ratio of CD4/CD8. In the study by Park et al., it
was shown that the ratio of CD4/CD8 did not change [45]. In the
study by Lee et al., they found no immunological rejection
responses in any of the subjects, based on the ratio of CD4-posi-
tive to CD8-positive T cells [55].
The remaining case series did not use any biochemical assays
to evaluate the possible immune reaction. Fang et al. was the ﬁrst
to use allogeneic ASC for the treatment of steroid resistant graft
versus host disease, and they presented a case series of six
patients [81]. They noted no adverse events related to the ASC
infusion. Fang et al. also conducted a study using allogeneic ASC
obtained from haploidentical donors, and cells were infused intra-
venously for the treatment of chronic refractory immune throm-
bocytopenic purpura, also without any mention of adverse effects
[83]. De la Portilla described the use of an immunological assess-
ment, but it was not mentioned in the Results section [38]. It was
described that two patients were withdrawn from the study due
to adverse events possibly due to treatment (pyrexia and perianal
abscess); however, in the setting of treating perianal ﬁstulas these
events cannot necessarily be attributed to the allogeneic cells
used. Oner et al. presented their results of a phase l trial adminis-
tering subretinal allogeneic ASC for treatment of advanced stage
retinitis pigmentosa [86]. They included 11 patients and did not
describe any form of immunological reaction.
In the present studies, only ASCs were administered in alloge-
neic fashion. Several different biochemical tests were applied in
the studies of which the CD4/CD8, cytokine levels and unspeciﬁc
IgM and IgG did not reveal any sign of activated immune response
toward the foreign cells. Only the two studies testing for donor-
speciﬁc antibodies revealed that 19%–34% of patients developed
these which suggest that the cells are not as immune privileged as
once thought. The consequences of these reactions are unknown.
Oncological Safety
The oncological safety was evaluated for studies administering
cells in the setting of previous malignancy (Table 1). This included
ﬁve studies (all case series) with a follow-up in the range of 3–12
months. Perez-Cano et al. published a study including 67 patients
where ADRC were injected into patients with previous breast can-
cer, where treatment was given as a cell-assisted lipotransfer [27].
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Table 1. Overview of safety analysis regarding thromboembolic safety and mortality, immunological as well as oncological safety
Thromboembolic safety and mortality
Author Study type Administration route Cell type TE complications Mortality Follow-up
Cardiac
Comella et al. [73] Case series Transendocardial ADRC 1/28 3/28 6
Henry et al. [76] RCT Intramyocardial ADRC 3/17 (1/14) 2/17 (0/14) 12
Houtgraaf et al. [74] RCT Intracoronary ADRC – – 6
Perin et al. [75] RCT Transendocardial ADRC 1/21 (1/6) 3/21 (2/6) 36
Immunological
Vanikar et al. [82] RCT Intravenous alloASC 6/95 (9/190) 7/95 (20/190) 6
Fang et al. [81] Case series Intravenous alloASC 0/6 2/6 40
Fang et al. [83] Case series Intravenous alloASC 0/7 0/7 8
Pulmonary
Zheng et al. [84] RCT Intravenous alloASC 0/6 (0/6) 1/6 (2/6) 1
Rheumatological
Alvares Garcia et al. [61] RCT Intravenous alloASC 1/46 (0/7) 0/46 (0/7) 6
Immunological safety
Author Study type Administration route Cell type Complications Biochemical reaction Follow-up
Gastrointestinal
Park et al. [45] Case series Wall of ﬁstula alloASC 0/6 CD4/CD8: N.s.i. 6
Panes et al. [44] RCT Wall of ﬁstula alloASC N.d. ASC/HLA-I: 34% 6
Garcia-Arranz et al. [39] Case series Wall of ﬁstula alloASC 0/10 Cytokine/US: N.s.i. 12
De la Portilla et al. [38] Case series Wall of ﬁstula alloASC Fever: 1/24 – 4
Immunological
Fang et al. [83] Case series Intravenous alloASC 0/7 – 8
Fang et al. [81] Case series Intravenous alloASC 0/6 – 40
Vanikar et al. [82] RCT Intravenous alloASC N.d. – 6
Muskuloskeletal
Lee et al. [55] Case series Intratendinous alloASC 0/12 CD4/CD8: N.s.i. 12
Ophthalmological
Oner et al. [86] Case series Subretinal alloASC 0/11 – 6
Pulmonary
Zheng et al. [84] RCT Intravenous alloASC 0/6 (0/6) – 1
Rheumatological
Alvaro-Gracia et al. [61] RCT Intravenous alloASC Fever: 9/46 (0/7)
Infections:
20/46 (0/7)
Rash: 2/46 (0/7)
ASC/HLA-I: 19%. 6
Oncological Safety
Author Study type Administration route Cell type Local recurrence Metastasis Follow-up
Soft tissue, breast
Aronowitz et al. [19] Case series Subcutaneous ADRC 1/54 0/54 12
Perez-Cano et al. [27] Case series Subcutaneous ADRC 0/67 1/67 12
Urogenital
Choi et al. [72] Case series Transurethral ADRC 0/6 0/6 3
Gotoh et al. [68] Case series Periurethral ADRC 0/9 0/9 6
Haahr et al. [70] Case series Corpus cavernosum ADRC 0/17 0/17 6
Abbreviations: –, not described/not performed; CD4/CD8, CD4 to CD8 ratio; N.d., no difference in adverse events between groups. no immunologi-
cal adverse events; N.s.i., no sign of immune rejection; alloASC, allogeneic ASC; ASC/HLA-I, ASC-speciﬁc anti-HLA-I antibodies; Cell type, ADRC were
autologous in all cases; cytokine/US, cytokine and unspeciﬁc antibodies. Data shown as treatment group count/total (control count/total); mortality,
all-cause mortality; TE, thromboembolic.
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Herein no cases of local recurrence were described, but one case
of pelvic metastasis was observed without exact note of timing.
Four other serious adverse events were noted; however, only one
of these was described, which was donor site bleeding following
liposuction. In another study, Aronowitz et al. found that of the 54
patients with previous breast cancer, one patient developed a
recurrence after cell-assisted lipotransfer with ADRC 11 months
after treatment [19].
A study by Gotoh et al. gave a similar treatment with ADRC as
a cell-assisted lipotransfer for urinary incontinence, in which 9/11
patients were previously treated for prostate cancer [87]. Here
they found no evidence of recurrence during the 1-year follow-up.
In a similar population group Haahr et al. injected ADRC intraca-
vernosal to patients with erectile dysfunction due to previous
prostate cancer surgery [70]. The authors did not describe any
case of recurrence in their 6-month follow-up study. Similarly, to
treat urinary incontinence following prostatectomy, Choi et al.
administered ADRC as a cell-assisted lipotransfer to six patients
[72]. They described no cases of recurrence or any other side
effects in their 3-month follow-up study.
All studies included in the evaluation of oncological safety
used autologous ADRC for treatment. There was only one case of
local breast cancer recurrence out of a total of 121 patients across
two studies within the 12-month follow-up periods. The remaining
three studies applied ADRC in 32 previous prostate cancer
patients and observed no recurrences within the follow-up period,
ranging from 3 to 6 months. For determining long-term oncologi-
cal safety, follow-up periods of several years are necessary to
ensure that cell therapy is safe.
Bias
All studies with a comparison group were included in the analysis
for bias looking speciﬁcally at the safety outcome (Table 2); 27
studies were eligible for inclusion. Only seven studies had proper
randomization and allocation concealment. For the outcome
safety, only ﬁve studies described proper blinding of patient, per-
sonnel and outcome assessor. Three of these studies were with
ADRC and described proper blinding with the introduction of lipo-
suction and subsequent sham ADRC injection [74–76].
Table 2. Risk of bias analysis
Random
sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Other
bias
Alvaro-Garcia et al. 2016 [61]
Castillo-Cardiel et al. 2015 [49]
Chang et al. 2013 [20]
Garcia-Olmo et al. 2009 [41]
Gentile et al. 2012 [23]
Gentile et al. 2014 [22]
Guadalajara et al. 2012 [42]
Han et al. 2009 [66]
Henry et al. 2016 [76]
Herreros et al. 2012 [43]
Houtgraaf et al. 2012 [74]
Koh et al. 2012 [54]
Koh et al. 2012 [34]
Koh et al. 2014 [51]
Koh et al. 2016 [52]
Kølle et al. 2013 [24]
Li et al. 2013 [25]
Marino et al. 2013 [67]
Onesti et al. 2016 [60]
Panes et al. 2016 [44]
Peltoniemi et al. 2013[28]
Perin et al. 2014 [75]
Sterodimas et al. 2011 [29]
Tanikawa et al. 2013 [30]
Tissiani et al. 2016 [61]
Vanikar et al. 2014 [82]
Zheng et al. 2014 [84]
Low risk Unclear High risk
Color codes
All studies with a control group were included for the analysis. Green: Low risk of bias, Yellow: Unclear risk of bias, Red: High risk of bias.
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DISCUSSION
The clinical translation process of adipose-derived cell products
has begun, and it is crucial that implementation of cell therapy is
based on the standard principles of evidence-based medicine.
Presently, cell therapy is widely considered as being equivalent to
pharmaceutical drugs, which implies that cell therapies should
adhere to the same standards for implementation as any newly
developed drug, including the assessment of safety and adverse
events.
This review includes more than 1,400 patients treated with
adipose-derived cell therapy with follow-up ranging from less than
a month to 3 years [75, 84]. Very few adverse events have been
reported that can be related directly to the cell therapy, Events
were rather related to the harvesting of adipose tissue, trauma
associated with injection, or the nature of the underlying condition
being treated. Of all studies administering ASCs systemically, a case
of pulmonary thromboembolism [73], as well as cases of myocar-
dial and cerebral infarctions were described [75, 76]. These are seri-
ous adverse events that can be fatal and since there is no clear
clinical evidence for the efﬁcacy of adipose-derived cell therapy as
of yet, future studies administering cells systemically should be cau-
tious and monitor for these possible serious adverse events. The
studies did not describe whether the cells were ﬁltered before
administration to ensure that the injected cells were single cell sus-
pensions. Thromboembolic complication risk can be assumed to be
higher when injecting clumped cells compared with single cell sus-
pensions. In addition, the underlying condition must also be taken
into account as the included patients had a poor prognosis.
Several studies used allogeneic ASC treatment and there was
no clear evidence of a clinical immune response. However, for
studies examining the presence and later production of donor-
speciﬁc antibodies, 19%–34% of patients developed these anti-
bodies suggesting that indeed there is a cellular response occur-
ring toward the allogeneic cells [44, 61]. The consequence of this,
if any, still remains unknown. In many instances it can be ques-
tioned whether the use of allogeneic ASCs has any value over
autologous cells, as many of the treated conditions are not acute
and life threatening, leaving room and time for the easy, simple
isolation and culture-expansion of ASCs. The use of ADRCs has the
advantages of being completely autologous and requires much
less advanced facilities as treatment can be offered as a same day
procedure with everything needed being available in the operat-
ing theatre [88]. On the other hand, the advantage of ASCs is the
fact that an almost unlimited number of cells can be obtained and
is also a more realistic option if one was to consider cell banking
either as autologous or allogeneic treatment modalities, and already
some studies have been published with funding from companies
seeking to offer off-the-shelf allogeneic ASC therapy [44, 61].
Another concern is the use of cell therapy in areas with previ-
ous malignancy, as preclinical data have suggested that cell
therapy can aggravate any remaining cancer cells [12–14]. How-
ever, this has so far not been shown in the clinical setting, as we
only could identify one case of recurrence following cell-assisted
lipotransfer among 121 breast cancer patients, which is well
within what could be expected [89]. It is vital in the setting of pre-
vious cancer treatment that safety evaluations are conducted
thoroughly with sufﬁciently long follow-up times, so these initial
uplifting results can be conﬁrmed.
During the last 5 years, there has been a marked increase in
the number of adipose-derived cell therapy clinical trials that have
been published; however, at present most of them are at the case
series level (Level IV evidence). In general, it is recognized that low
quality studies increase risk of bias, which leads to an increasing
chance of ﬁndings that do not represent reality [90]. Therefore, it
is important to transition toward well-conducted randomized con-
trolled trials with adequate blinding, which also includes the
safety assessment.
A systematic review can only be as good as the available litera-
ture allows it to be, and this review was limited by the fact that so
many studies did not clearly describe their method of assessing
safety, and in the end, you will only ﬁnd the adverse events that
you are looking for. Another limitation of the review is the possi-
bility of small overlap in some of the included studies, as case
series were published over time from the same research groups
with an increasing number of patients; this was deemed to be of
such a small magnitude that it was insigniﬁcant.
While adipose-derived cell therapy has shown great potential
so far, there is very sparse clinical evidence to promote routine
clinical implementation. There is a need for higher quality studies
before rational conclusions can be made regarding the efﬁcacy of
adipose-derived cell therapies. Future studies should place a
larger emphasis on including a placebo/sham treatment for
proper blinding of both patients and assessors. This is especially
crucial when the primary outcome is subjective due to the pla-
cebo response [91].
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